Want to see FENC full AI Analyst Report?
Fennec Pharmaceuticals (FENC) Ratios
Fennec Pharmaceuticals Ratios
FENC's free cash flow for Q2 2026 was $50.00K. For the 2026 fiscal year, FENC's free cash flow was increased by $0.00 and operating cash flow was $50.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.34 | 6.38 | 3.56 | 5.80 | 13.54 |
| Quick Ratio | 6.19 | 6.22 | 3.27 | 5.67 | 13.54 |
| Cash Ratio | 3.50 | 3.85 | 1.76 | 5.16 | 12.76 |
| Solvency Ratio | -0.28 | 0.01 | -0.41 | -0.80 | -0.04 |
| Operating Cash Flow Ratio | -1.19 | 3.90 | -2.27 | -3.92 | -8.60 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 31.55M | $ -6.69M | $ -11.63M | $ -2.78M | $ 15.74M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.43 | 1.15 | 0.92 | 0.22 |
| Debt-to-Equity Ratio | 0.00 | -3.29 | -2.66 | -9.69 | 0.32 |
| Debt-to-Capital Ratio | 0.00 | 1.44 | 1.60 | 1.12 | 0.24 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 1.44 | 1.60 | 1.12 | 0.24 |
| Financial Leverage Ratio | 2.00 | -7.65 | -2.31 | -10.49 | 1.42 |
| Debt Service Coverage Ratio | -3.63 | 1.09 | -3.73 | -23.40 | -137.26 |
| Interest Coverage Ratio | -3.05 | 0.61 | -3.76 | -23.10 | -136.69 |
| Debt to Market Cap | 0.00 | 0.11 | 0.10 | 0.10 | 0.04 |
| Interest Debt Per Share | 0.07 | 0.86 | 1.29 | 0.98 | 0.20 |
| Net Debt to EBITDA | 4.93 | -1.52 | -1.40 | -0.05 | 0.94 |
| Profitability Margins | |||||
| Gross Profit Margin | 91.57% | 93.30% | 94.08% | 94.40% | 0.00% |
| EBIT Margin | -16.92% | 8.41% | -59.53% | -1481.17% | 0.00% |
| EBITDA Margin | -16.69% | 10.09% | -59.53% | -1481.17% | 0.00% |
| Operating Profit Margin | -14.22% | 5.21% | -60.09% | -1471.60% | 0.00% |
| Pretax Profit Margin | -21.58% | -0.15% | -75.50% | -1544.89% | 0.00% |
| Net Profit Margin | -21.82% | -0.92% | -75.50% | -1554.46% | 0.00% |
| Continuous Operations Profit Margin | -21.82% | -0.92% | -75.50% | -1544.89% | 0.00% |
| Net Income Per EBT | 101.10% | 614.08% | 100.00% | 100.62% | 100.63% |
| EBT Per EBIT | 151.83% | -2.86% | 125.64% | 104.98% | 100.71% |
| Return on Assets (ROA) | -13.90% | -0.97% | -59.73% | -88.57% | -77.88% |
| Return on Equity (ROE) | -27.79% | 7.43% | 138.06% | 928.80% | -110.68% |
| Return on Capital Employed (ROCE) | -10.65% | 6.52% | -66.13% | -101.16% | -82.96% |
| Return on Invested Capital (ROIC) | -10.65% | 6.52% | -66.06% | -101.16% | -82.96% |
| Return on Tangible Assets | -13.90% | -0.97% | -59.73% | -88.57% | -77.88% |
| Earnings Yield | -4.43% | -0.25% | -5.28% | -9.40% | -15.23% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.93 | 3.69 | 2.41 | 0.99 | 0.00 |
| Payables Turnover | 0.81 | 0.98 | 0.33 | 0.04 | 0.00 |
| Inventory Turnover | 2.41 | 3.00 | 0.58 | 0.15 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.64 | 1.06 | 0.79 | 0.06 | 0.00 |
| Working Capital Turnover Ratio | 0.96 | 1.68 | 1.03 | 0.07 | 0.00 |
| Cash Conversion Cycle | -107.65 | -151.10 | -318.86 | -7331.58 | 0.00 |
| Days of Sales Outstanding | 189.51 | 98.92 | 151.38 | 367.38 | 0.00 |
| Days of Inventory Outstanding | 151.48 | 121.51 | 625.05 | 2444.65 | 0.00 |
| Days of Payables Outstanding | 448.64 | 371.53 | 1095.29 | 10143.60 | 0.00 |
| Operating Cycle | 341.00 | 220.44 | 776.43 | 2812.03 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.44 | 0.99 | -0.65 | -0.69 | -0.55 |
| Free Cash Flow Per Share | -0.44 | 0.99 | -0.65 | -0.69 | -0.55 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 1.40 | -0.55 | -0.73 | -2.85 |
| Operating Cash Flow to Sales Ratio | -0.28 | 0.57 | -0.81 | -11.76 | 0.00 |
| Free Cash Flow Yield | -5.67% | 15.64% | -5.64% | -7.12% | -12.41% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -21.39 | -395.00 | -18.93 | -10.63 | -6.57 |
| Price-to-Sales (P/S) Ratio | 4.93 | 3.63 | 14.29 | 165.29 | 0.00 |
| Price-to-Book (P/B) Ratio | 6.28 | -29.38 | -26.13 | -98.76 | 7.27 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -17.64 | 6.39 | -17.72 | -14.05 | -8.06 |
| Price-to-Operating Cash Flow Ratio | -17.64 | 6.39 | -17.72 | -14.05 | -8.06 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 4.06 | 0.56 | -0.30 | 0.55 |
| Enterprise Value Multiple | -24.60 | 34.43 | -25.41 | -11.21 | -5.73 |
| Enterprise Value | 183.32M | 165.20M | 321.41M | 254.85M | 98.51M |
| EV to EBITDA | -24.60 | 34.43 | -25.41 | -11.21 | -5.73 |
| EV to Sales | 4.11 | 3.48 | 15.12 | 166.03 | 0.00 |
| EV to Free Cash Flow | -14.70 | 6.12 | -18.75 | -14.11 | -6.93 |
| EV to Operating Cash Flow | -14.70 | 6.12 | -18.75 | -14.11 | -6.93 |
| Tangible Book Value Per Share | 1.23 | -0.22 | -0.44 | -0.10 | 0.61 |
| Shareholders’ Equity Per Share | 1.23 | -0.22 | -0.44 | -0.10 | 0.61 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | -5.14 | 0.00 | -0.01 | -0.01 |
| Revenue Per Share | 1.56 | 1.74 | 0.80 | 0.06 | 0.00 |
| Net Income Per Share | -0.34 | -0.02 | -0.60 | -0.91 | -0.67 |
| Tax Burden | 1.01 | 6.14 | 1.00 | 1.01 | 1.01 |
| Interest Burden | 1.28 | -0.02 | 1.27 | 1.04 | 1.01 |
| Research & Development to Revenue | 0.01 | 0.01 | 0.00 | 2.30 | 0.00 |
| SG&A to Revenue | 1.05 | 0.87 | 0.97 | 11.55 | 0.00 |
| Stock-Based Compensation to Revenue | 0.16 | 0.11 | 0.25 | 2.75 | 0.00 |
| Income Quality | 1.21 | -61.88 | 1.07 | 0.76 | 0.82 |
Currency in USD
